trilaciclib + envafolimab + docetaxel

This is an investigational combination therapy consisting of three agents: - **Trilaciclib** is a small molecule, intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that induces transient G1 cell cycle arrest in hematopoietic stem and progenitor cells, providing myeloprotection during chemotherapy by reducing chemotherapy-induced myelosuppression. - **Envafolimab** is a humanized single-domain monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses. - **Docetaxel** is a microtubule-stabilizing chemotherapeutic agent that inhibits cell division. The combination aims to leverage trilaciclib’s myeloprotective effects to reduce the hematologic toxicity of docetaxel-based chemotherapy while combining the cytotoxic activity of docetaxel with the immunotherapeutic effect of envafolimab. This regimen is under clinical investigation for advanced or metastatic non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC)[1][2][9].